Alnylam Pharmaceuticals’ (ALNY) Neutral Rating Reiterated at Cantor Fitzgerald

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “neutral” rating restated by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $150.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target suggests a potential downside of 38.27% from the stock’s current price.

A number of other equities research analysts have also recently commented on ALNY. Citigroup raised their price objective on Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the company a “buy” rating in a research note on Tuesday, June 25th. Wells Fargo & Company lifted their price target on shares of Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the company an “equal weight” rating in a research report on Tuesday, June 25th. StockNews.com upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, April 29th. Royal Bank of Canada raised their price objective on shares of Alnylam Pharmaceuticals from $235.00 to $250.00 and gave the company an “outperform” rating in a research note on Tuesday, June 25th. Finally, Morgan Stanley boosted their target price on shares of Alnylam Pharmaceuticals from $164.00 to $250.00 and gave the stock an “equal weight” rating in a research report on Tuesday, June 25th. Eight research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $246.41.

Alnylam Pharmaceuticals Stock Down 1.6 %

Shares of NASDAQ ALNY opened at $243.00 on Monday. The firm has a market cap of $30.74 billion, a PE ratio of -90.67 and a beta of 0.37. The company’s fifty day simple moving average is $159.86 and its 200 day simple moving average is $164.56. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $252.87.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The company had revenue of $494.33 million for the quarter, compared to the consensus estimate of $428.01 million. Alnylam Pharmaceuticals’s revenue for the quarter was up 54.8% compared to the same quarter last year. During the same period last year, the company earned ($1.40) EPS. On average, equities analysts predict that Alnylam Pharmaceuticals will post -3.92 earnings per share for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $276,726.02. Following the completion of the transaction, the executive vice president now owns 14,181 shares in the company, valued at $3,275,669.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Yvonne Greenstreet sold 8,301 shares of the business’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the sale, the chief executive officer now directly owns 80,534 shares in the company, valued at approximately $18,602,548.66. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $276,726.02. Following the completion of the transaction, the executive vice president now owns 14,181 shares of the company’s stock, valued at approximately $3,275,669.19. The disclosure for this sale can be found here. In the last 90 days, insiders sold 67,357 shares of company stock valued at $13,436,711. 1.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Teachers Retirement System of The State of Kentucky increased its holdings in shares of Alnylam Pharmaceuticals by 8.1% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 33,213 shares of the biopharmaceutical company’s stock worth $4,964,000 after purchasing an additional 2,500 shares during the period. Cetera Advisors LLC purchased a new position in Alnylam Pharmaceuticals during the first quarter worth about $238,000. Burney Co. increased its stake in Alnylam Pharmaceuticals by 371.9% in the 1st quarter. Burney Co. now owns 27,059 shares of the biopharmaceutical company’s stock worth $4,044,000 after acquiring an additional 21,325 shares during the last quarter. Swedbank AB purchased a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter valued at about $3,084,000. Finally, Plato Investment Management Ltd boosted its position in shares of Alnylam Pharmaceuticals by 2,666.3% during the 1st quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock valued at $674,000 after acquiring an additional 4,346 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.